OLEMA PHARMACEUTICALS, INC. Number of Reportable Segments
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. number of reportable segments for the quarter ending 2023-03-31 was 1.00 segment, a 0.00% change year-over-year.
- OLEMA PHARMACEUTICALS, INC. number of reportable segments for the quarter ending 2022-03-31 was 1.00 segment, a 0.00% change year-over-year.
- OLEMA PHARMACEUTICALS, INC. number of reportable segments for the quarter ending 2021-03-31 was 1.00 segment.
- OLEMA PHARMACEUTICALS, INC. number of reportable segments for fiscal 2022 was 1.00 segment, a 0.00% change from fiscal 2021.
- OLEMA PHARMACEUTICALS, INC. number of reportable segments for fiscal 2021 was 1.00 segment.
segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2023-09-30 | 1.00 segment 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | 1.00 segment 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | 1.00 segment 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | 1.00 segment 10-K · filed 2023-03-09 | |||
| 2022-09-30 | 1.00 segment 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | 1.00 segment 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | 1.00 segment 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | 1.00 segment 10-K · filed 2022-02-28 | |||
| 2021-09-30 | 1.00 segment 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | 1.00 segment 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | 1.00 segment 10-Q · filed 2021-05-11 |
Segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-03-16 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | 1.00 Segment 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | 1.00 Segment 10-K · filed 2025-03-18 | |||
| 2024-09-30 | 1.00 Segment 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | 1.00 Segment 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | 1.00 Segment 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | 1.00 Segment 10-K · filed 2024-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |